MRNA monthly performance report
Monthly MRNA research: returns, drawdown, relative strength, seasonality, and key stats.
MRNA monthly report
—
Key takeaways
- Moderna (MRNA) closed August 2026 at $56.26, up 2.63% for the month and +104.81% over the trailing 12 months.
- Year-to-date, MRNA is +90.78%, outperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +24.49% versus its 200-day moving average ($45.19), a bullish technical signal.
- Over the past three years, MRNA has underperformed the S&P 500 by −120.28%, with a relative strength index reading of 32.5.
- Win rate over the trailing 39 months stands at 41% — 16 positive months versus 23 negative months.
Moderna ended August 2026 at $56.26, posting a monthly return of +2.63%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −0.42%.
The current quarter stands at −22.69% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +24.49% versus the 200-day moving average ($45.19).
Year-to-date, MRNA is +90.78% against SPY +12.89%, a gap of +77.89%. The stock is currently −34.28% below its 52-week high, with maximum 3-year drawdown at −86.58%.
| Period | MRNA | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −1.28% | −0.20% | −1.08% |
| 1 Week | +0.81% | +3.90% | −3.10% |
| 1 Month | +2.63% | +3.05% | −0.42% |
| 3 Months | +22.46% | +7.11% | +15.35% |
| 6 Months |